V-Bio Ventures
Venture capitalGhent · Seed–Growth · 13 people tracked
Investment thesis
V-Bio Ventures backs private life science companies with differentiated technologies that address unmet needs and offer high societal or environmental impact potential. The fund focuses on therapeutics, spanning both drug discovery and drug development, and co-creates startups in addition to investing in early- to mid-stage ventures. It maintains a preferred relationship with the Belgian research institute VIB, building some companies on VIB-derived innovation, while also sourcing deals from other research institutes, entrepreneurial initiatives, and corporate spin-outs. The firm concentrates geographically on Europe and offers more than capital through its network and sector expertise.
Source: firm website, verified Aug 7, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 19 of 22 portfolio companiesBiotech ×18Healthtech ×8Deep Tech ×6Medical Devices ×4AgTech ×3AI & Machine Learning ×3Enterprise Software ×1FoodTech ×1
HQs:France×3Belgium×2Italy×1Netherlands×1United States×1
Investments · 22 tracked
founders shown can be your intro path
Protealis breeds legume crops such as soybeans and yellow peas and develops proprietary seed coatings with nitrogen-fixing bacteria adapted to the European climate.
AgTechBiotechFoodTechGent, BE
Benjamin Laga(Co-founder & CEO)Jonas Aper(Co-founder & Director of Breeding)
Co-investorsAgri Investment FundInnovation IndustriesKorysEstari GroupVIBPMV
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)Pietro Faccioli(Co-founder)Giovanni Spagnolli(Co-founder, CTO)Maria Letizia Barreca(Co-founder)Graziano Lolli(Co-founder)
Co-investors3B Future Health FundCDP Venture CapitalSeroba Life SciencesVertis SGRVI PartnersClaris Ventures
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.
BiotechHealthtechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
Co-investorsEQT Life SciencesAdBio partnersAndera PartnersAsabys PartnersCanaan PartnersPontifax Venture Capital+1 more
Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.
AI & Machine LearningEnterprise SoftwareSaaS
Co-investorsPebblebedAndera PartnersBGVForbionFountain Healthcare PartnersHTGF+2 more
Animab is a biotechnology company developing oral antibody-based products that target intestinal pathogens to improve gut health in livestock, with a focus on protecting piglets during the post-weaning stage.
AgTechBiotechDeep Tech
Co-investorsAgri Investment FundPMVQbic Fund
Aphea.Bio develops biological crop protection products and biostimulants, including bioinsecticides targeting crop pests.
AgTechBiotech
Co-investorsAstanor VenturesEuropean Circular Bioeconomy FundInnovation IndustriesPMV
Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.
BiotechHealthtech
Co-investors+ND Capital
ATB Therapeutics develops targeted antibody therapies, including its "atbody" format, for hematological malignancies, autoimmune diseases, and solid tumors.
BiotechHealthtech
Co-investorsMRL Ventures FundVIVES Partners
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Co-investorsAdBio partnersJeito CapitalNovo HoldingsPMVAsabys Partners
Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases.
AI & Machine LearningBiotech
Co-investorsBioGeneration VenturesEQT Life SciencesBOMCurie CapitalKurma Partners
Biodol Therapeutics is a biotech company developing proprietary FLT3 inhibitors (BDT compounds) at the preclinical stage to treat neuropathic and chronic pain, including opioid-combination indications.
BiotechMedical DevicesMontpellier, FR
Coave Therapeutics is a biotech company developing gene therapies based on AAV vector engineering and genetic construct design, targeting neurodegenerative and ocular diseases.
BiotechHealthtechParis, FR
Co-investorsFund+Kurma PartnersSeroba Life SciencesBpifranceInvusNovo Holdings+1 more
Co-investorsCapricorn Venture PartnersFund+PMVQuest for GrowthBioGeneration Ventures
Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications.
BiotechHealthtech
Co-investorsFountain Healthcare PartnersInvivo Capital PartnersJeito CapitalKurma PartnersLifeArc VenturesOrbiMed
ExeVir is a clinical-stage biotech developing single domain antibody (VHH) therapies to prevent and treat infectious diseases, with an initial focus on COVID-19 and dengue.
BiotechDeep TechHealthtech
Co-investorsFund+VIVES Partners
Muna Therapeutics is a biotechnology company that discovers and develops therapies aimed at slowing or stopping neurodegenerative diseases, including Alzheimer's and Parkinson's.
BiotechLongevity
Rita Balice-Gordon(Founder)in
Co-investorsDroia VenturesSanofi VenturesSofinnova Partners
Orionis Biosciences discovers and engineers molecules that connect proteins on or within cells to reprogram disease-driving processes or activate immune responses.
BiotechDeep TechNewton, US
Nikolai Kley(Founder)Nikolai Kley, Ph.D.(Executive Officer, Director)
BoardGriet Vanpoucke, Ph.D.(Director)Steven R. Gullans, Ph.D.(Director)
Co-investorsExcel Venture ManagementSolari CapitalSolasta VenturesWessel Management
Co-investorsBioMedPartnersHealthCapPontifax Venture CapitalInkef
Develops electric weed control technology using high-frequency AC to destroy weeds to the roots, as an alternative to chemical herbicides.
Co-investorsAgri Investment FundOxford Investment Opportunity Network (OION)The Yield LabThe Yield Lab Europe
Step Pharma develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor in clinical development as a targeted oncology therapy for blood cancers such as lymphoma and essential thrombocythaemia as well as solid tumours including ovarian cancer.
BiotechDeep TechMedical DevicesSaint-Genis-Pouilly, FR
Co-investorsHadean VenturesKurma PartnersPontifax Venture CapitalSunstone Capital
Portfolio news
latest coverage across their companiesAgomab Therapeutics · investing.com · Aug 10, 2026
Coave Therapeutics · biopharminternational.com · May 26, 2026
Step Pharma · biospace.com · Oct 16, 2025
Avidicure · avidicure.com · Jun 27, 2025
Frequently asked questions
- How many investments has V-Bio Ventures made?
- V-Bio Ventures has 21 tracked investments.
- What stage does V-Bio Ventures invest at?
- V-Bio Ventures invests at the Seed, Series A, Series B, Growth stages.
- What is V-Bio Ventures's typical check size?
- V-Bio Ventures typically writes checks of $270K – $2.2M.
- What sectors does V-Bio Ventures focus on?
- V-Bio Ventures focuses on AgTech, Biotech, Healthtech, Longevity, Medical Devices.
- Where is V-Bio Ventures located?
- V-Bio Ventures is headquartered in Ghent, BE.
- Who does V-Bio Ventures co-invest with?
- V-Bio Ventures most often shares deals with PMV, Fund+, Kurma Partners, among 43 tracked co-investors.
Images
Similar investors
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
AgeTech Capital is a purpose-driven private market investment firm backing technology solutions that support healthier, wealthier and more fulfilling aging.